Market Conditions and Cost Pressures are Prompting Redesign of Manufacturing Facilities
This article was originally published in The Gold Sheet
Executive Summary
The pharmaceutical and biotech manufacturing facilities of the future will be smaller and simpler than existing facilities, have more closed processes, combine clinical and commercial operations under one roof, and use more disposable equipment. Cost pressures and market conditions are behind some of these anticipated changes, some of which are occurring right now.
You may also be interested in...
Industry Applauds US FDA Plans For Novel Excipients Review Pathway, But Urges Refinement
The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.
Biologics Consortium Plans Collaborative Approach To Rapid Methods Validation
A plan to develop a “best practices” guide on validating rapid analytical methods for biopharmaceuticals is in the works.
US FDA Finds Negligible Cancer Risks In Metformin Products
The US FDA finds metformin meets NDMA impurity threshold and urges diabetics to continue taking it.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: